Figure 3B shows that anti-CRD4-MR scFv #B2 could completely block tumor-cell released mesothelin binding to CD206high macrophages, while the blocking activities of anti-CRD4-MR scFvs #G11 and #H11 were intermediate or low, respectively (Fig. 3C,D). Anti-CRD4-MR scFv #G11 and #B2 could also block mesothelin binding to CD206low macrophages co-cultured with tumor cells (Fig. 4B–D). Here, NR3C2 is linked to neoplasm.